Share This Page
Drugs in ATC Class A05AA
✉ Email this page to a colleague
Up to Top Level ATC Classes
Up to A - Alimentary tract and metabolism
Up to A05 - BILE AND LIVER THERAPY
Up to A05A - BILE THERAPY
Drugs in ATC Class: A05AA - Bile acids and derivatives
| Tradename | Generic Name |
|---|---|
| CHOLBAM | cholic acid |
| OBETICHOLIC ACID | obeticholic acid |
| OCALIVA | obeticholic acid |
| >Tradename | >Generic Name |
Market Dynamics and Patent Landscape for ATC Class A05AA – Bile Acids and Derivatives
What is the Scope of ATC Class A05AA?
ATC (Anatomical Therapeutic Chemical) classification code A05AA pertains to bile acids and derivatives, primarily comprising ursodeoxycholic acid (ursodiol) and related compounds. These agents are used in the management of liver and gallbladder diseases, such as primary biliary cirrhosis, cholestasis, and gallstone dissolution.
What Are Current Market Drivers?
Market growth for ATC A05AA compounds stems from multiple factors:
- Increased prevalence of liver diseases: Rising cases of primary biliary cirrhosis, cholestasis, and gallstones fuel demand.
- Expanded indications: Use in nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) under investigation.
- Aging populations: Greater occurrence of liver-related conditions among older demographics.
- Advances in formulation technology: Development of combination therapies and improved delivery methods.
The global market value reached approximately USD 300 million in 2022, projected to grow at a compound annual growth rate (CAGR) of 4% to 5% through 2030.
How Does the Patent Landscape Evolve?
Key Patents and Their Expiry Timeline
The patent portfolio for bile acids and derivatives involves composition patents, method-of-use patents, and formulation patents. The landscape shows:
- Original composition patents for ursodeoxycholic acid, filed in the 1970s and 1980s, generally expired or are close to expiration.
- Recent innovations focus on formulations and new derivatives, with patents filed mainly from 2000 onward.
- Several patents on combination therapies and unique delivery systems are active, with expiry dates around 2030-2035.
Major Patent Holders
- HepaPharm Ltd.: Patents on novel formulations and delivery methods of ursodeoxycholic acid.
- Genkyotex: Patents related to derivatives with enhanced bioavailability.
- Ikaria Inc. (now part of Mallinckrodt): Held patents on extended-release formulations.
- Others: Numerous universities and biotech firms patenting derivatives and methods of treatment.
Patent Filing Trends
Patent filings peaked between 2000 and 2010, correlating with increased research into alternative bile acid derivatives and combination treatments. Post-2015 filings focus on improved formulations, including nanoparticle encapsulation and targeted delivery.
Geographical Patent Activity
- United States: Largest number of filings, with strong patent activity extending to Europe and Asia.
- Europe: Focus on formulation innovations.
- Asia: Growing activity, especially in China and South Korea, primarily on derivatives and manufacturing processes.
What Are Recent Scientific and Regulatory Changes?
- The U.S. Food and Drug Administration (FDA) approved obeticholic acid (Ocaliva), a semi-synthetic derivative of chenodeoxycholic acid, for primary biliary cholangitis (2016). This spurred patent activity for other bile acid derivatives.
- The European Medicines Agency (EMA) approved similar indications, fostering a broader market presence.
- Investigational use in NASH and other metabolic syndromes has garnered regulatory interest, creating potential for first-mover advantage.
What Are Key Challenges and Opportunities?
Challenges:
- Patent expiration for main compounds reduces exclusivity.
- Availability of generic formulations pressures pricing.
- Complexity in securing patents on derivatives due to prior art.
Opportunities:
- Development of novel derivatives with enhanced efficacy.
- Patents on innovative delivery systems (e.g., nanoparticles).
- Expanding indications into NASH, metabolic syndrome, and cancer.
Summary of Market Trends
| Aspect | Status |
|---|---|
| Market size (2022) | USD 300 million |
| Projected CAGR (2023-2030) | 4%-5% |
| Patent activity (filings) | Declined post-2010, with recent focus on formulations and derivatives |
| Key approved drugs | Ursodiol, obeticholic acid (Ocaliva) |
| Major patent expiry | Around 2025-2030 for original compounds |
Key Takeaways
- The market for ATC A05AA compounds is growing modestly, driven by liver disease prevalence and new therapeutic applications.
- The patent landscape has become more complex, with primary patents expiring and innovation centered on formulations and derivatives.
- Competitive advantage now hinges on developing new compounds, delivery methods, and expanding into metabolic and oncological indications.
- Patent expiration of core products encourages generic entry but also fosters innovation in the derivatives space.
FAQs
-
What is the primary therapeutic use of bile acids in ATC class A05AA?
They are mainly used to treat liver diseases such as primary biliary cholangitis and cholestasis, aiding in gallstone dissolution and liver function improvement. -
When did obeticholic acid receive regulatory approval?
FDA approved obeticholic acid in 2016 for primary biliary cholangitis. -
What are the main patent expiry years for original bile acid compounds?
Patents filed in the late 1970s and 1980s generally expired between 2005 and 2015, with recent patents expiring around 2025-2030. -
Which regions show the most patent activity?
The U.S. leads, with significant activity in Europe and emerging activity in China and South Korea. -
What opportunities exist for new entrants?
Developing novel derivatives, improving delivery systems, and expanding indications into NASH and metabolic disorders.
References
[1] World Health Organization. (2022). Global Liver Disease Report.
[2] PatentScope. (2023). Patent filings related to bile acids and derivatives.
[3] U.S. Food and Drug Administration. (2016). Approval letter for Ocaliva.
[4] European Medicines Agency. (2017). Summary of opinion for obeticholic acid.
[5] MarketWatch. (2023). Global market analysis for bile acids and derivatives.
More… ↓
